blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3380525

EP3380525 - PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  06.10.2023
Database last updated on 27.07.2024
FormerGrant of patent is intended
Status updated on  18.05.2023
FormerExamination is in progress
Status updated on  21.10.2022
FormerRequest for examination was made
Status updated on  31.08.2018
FormerThe international publication has been made
Status updated on  02.06.2017
Most recent event   Tooltip26.07.2024Lapse of the patent in a contracting state
New state(s): CZ, RO		published on 28.08.2024 [2024/35]
Applicant(s)For all designated states
Immunogen, Inc.
830 Winter Street
Waltham, MA 02451 / US
[2018/40]
Inventor(s)01 / BARTLETT, Elizabeth
88 Park Avenue
Unit 207
Arlington, MA 02476 / US
 [2018/40]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[2023/45]
Former [2018/40]McNab, Donald C.
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
Application number, filing date16869289.523.11.2016
[2018/40]
WO2016US63624
Priority number, dateUS201562260104P25.11.2015         Original published format: US 201562260104 P
US201662368156P28.07.2016         Original published format: US 201662368156 P
[2018/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017091745
Date:01.06.2017
Language:EN
[2017/22]
Type: A1 Application with search report 
No.:EP3380525
Date:03.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.06.2017 takes the place of the publication of the European patent application.
[2018/40]
Type: B1 Patent specification 
No.:EP3380525
Date:08.11.2023
Language:EN
[2023/45]
Search report(s)International search report - published on:US01.06.2017
(Supplementary) European search report - dispatched on:EP15.10.2019
ClassificationIPC:C07K16/46, C07K16/28, C07D487/04
[2018/40]
CPC:
A61K9/0019 (EP,US); A61K31/5517 (EP,US); A61K39/39591 (EP,US);
A61K47/12 (EP,US); A61K47/183 (EP,US); A61K47/186 (EP,US);
A61K47/26 (EP,US); A61K47/68035 (EP,US); A61K47/6849 (EP,US);
A61P35/00 (EP); C07D519/00 (EP,US); C07K16/28 (EP,US);
C07K16/2803 (EP,US); C07K16/2866 (US); C07K2317/24 (EP,US);
C07K2317/56 (US); C07K2317/565 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/40]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PHARMAZEUTISCHE FORMULIERUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON[2018/40]
English:PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF[2018/40]
French:FORMULATIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION[2018/40]
Entry into regional phase25.06.2018National basic fee paid 
25.06.2018Search fee paid 
25.06.2018Designation fee(s) paid 
25.06.2018Examination fee paid 
Examination procedure25.06.2018Examination requested  [2018/40]
25.06.2018Date on which the examining division has become responsible
29.06.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
09.09.2020Amendment by applicant (claims and/or description)
25.10.2022Despatch of a communication from the examining division (Time limit: M04)
03.03.2023Reply to a communication from the examining division
19.05.2023Communication of intention to grant the patent
27.09.2023Fee for grant paid
27.09.2023Fee for publishing/printing paid
27.09.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23200032.3  / EP4335851
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
09.09.2020Request for further processing filed
09.09.2020Full payment received (date of receipt of payment)
Request granted
17.09.2020Decision despatched
Fees paidRenewal fee
27.11.2018Renewal fee patent year 03
27.11.2019Renewal fee patent year 04
27.11.2020Renewal fee patent year 05
29.11.2021Renewal fee patent year 06
28.11.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RO08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
[2024/35]
Former [2024/34]EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/33]HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/26]HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/25]HR08.11.2023
LT08.11.2023
PL08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/24]HR08.11.2023
LT08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/21]LT08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/20]GR09.02.2024
IS08.03.2024
Documents cited:Search[Y]WO2007019232  (IMMUNOGEN INC [US], et al);
 [Y]WO2015075201  (GENMAB AS [DK]);
 [Y]WO2015104385  (SYNTHON BIOPHARMACEUTICALS BV [NL]);
International search[Y]WO2005042029  (PSMA DEV COMPANY LLC [US], et al);
 [Y]US2006002942  (KUNZ ARTHUR [US], et al);
 [Y]US2012009181  (AB OLGA [US], et al);
 [Y]US2012009199  (DIMITROVA MARIANA N [US], et al);
 [Y]US2012238731  (FISHKIN NATHAN [US], et al);
 [Y]WO2014191560  (INNOVA BIOSCIENCES LTD [GB]);
 [Y]US2014369924  (WEISSMAN IRVING L [US], et al)
by applicantUS4444887
 EP0239400
 GB2188638
 US4716111
 WO9109967
 WO9110741
 EP0519596
 US5208020
 US5225539
 EP0592106
 EP0239400
 US5475092
 US5530101
 US5545806
 US5565332
 US5569825
 WO9634096
 WO9633735
 US5585089
 US5639641
 US5693761
 US5714352
 WO9816654
 WO9824893
 US5814318
 WO9846645
 WO9850433
 WO0002587
 US6265150
 WO02060955
 US6441163
 WO02092127
 US2002197266
 US6716821
 WO2005009369
 US6913748
 US2005169933
 US2006177455
 WO2007024222
 US7276497
 US7276499
 US7342110
 US7368565
 US7388026
 US7414073
 US7557189
 US2009274713
 WO2009134976
 US7834155
 WO2011106528
 WO2011112978
 US8119787
 US2012253021
 WO2012156455
 US8337855
 US8426402
 US8557966
 US8709432
 US8765917
 US8765740
 US8802667
 US8809320
 US8889669
 WO2015004385
 WO2015075201
 US9381256
 WO2017004026
 US9669102
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.